COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights Psychedelics Investing
Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million Pharmaceutical Investing
COMPASS Pathways announces publication of phase 2b study of COMP360 psilocybin therapy for treatment-resistant depression in The New England Journal of Medicine Psychedelics Investing
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results Pharmaceutical Investing
Silo Wellness Breaking News: Jackson County Oregon's Proposed TPM Restrictions Put Rural Psilocybin Retreat Therapy Centers at Risk Psychedelics Investing
Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc. Pharmaceutical Investing
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
